- Home
- EMN vs JAZZ Comparison
EMN vs JAZZ Comparison
Compare EMN & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMN
- JAZZ
- Stock Information
- Founded
- EMN 1920
- JAZZ 2003
- Country
- EMN United States
- JAZZ Ireland
- Employees
- EMN N/A
- JAZZ N/A
- Industry
- EMN Major Chemicals
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- EMN Industrials
- JAZZ Health Care
- Exchange
- EMN Nasdaq
- JAZZ Nasdaq
- Market Cap
- EMN 7.0B
- JAZZ 7.7B
- IPO Year
- EMN 1993
- JAZZ 2007
- Fundamental
- Price
- EMN $69.06
- JAZZ $129.50
- Analyst Decision
- EMN Buy
- JAZZ Strong Buy
- Analyst Count
- EMN 14
- JAZZ 14
- Target Price
- EMN $89.29
- JAZZ $178.93
- AVG Volume (30 Days)
- EMN 1.3M
- JAZZ 745.7K
- Earning Date
- EMN 10-30-2025
- JAZZ 11-05-2025
- Dividend Yield
- EMN 4.81%
- JAZZ N/A
- EPS Growth
- EMN N/A
- JAZZ N/A
- EPS
- EMN 7.12
- JAZZ N/A
- Revenue
- EMN $9,286,000,000.00
- JAZZ $4,086,695,000.00
- Revenue This Year
- EMN N/A
- JAZZ $5.65
- Revenue Next Year
- EMN $2.45
- JAZZ $5.79
- P/E Ratio
- EMN $9.69
- JAZZ N/A
- Revenue Growth
- EMN 1.52
- JAZZ 4.52
- 52 Week Low
- EMN $56.78
- JAZZ $95.49
- 52 Week High
- EMN $114.50
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- EMN 51.09
- JAZZ 67.67
- Support Level
- EMN $66.66
- JAZZ $127.52
- Resistance Level
- EMN $70.63
- JAZZ $133.00
- Average True Range (ATR)
- EMN 1.58
- JAZZ 2.90
- MACD
- EMN 0.61
- JAZZ 0.72
- Stochastic Oscillator
- EMN 70.76
- JAZZ 77.99
About EMN Eastman Chemical Company
Established in 1920 to produce chemicals for Eastman Kodak, Eastman Chemical has grown into a global specialty chemical company with manufacturing sites around the world. The company generates the majority of its sales outside of the United States, with a strong presence in Asian markets. During the past several years, Eastman has sold noncore businesses, choosing to focus on higher-margin specialty product offerings.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.